ArticleScientific reports2017
Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data.Frontiers in pharmacology · 2026Pooled it
- Impact ofBiology · 2026Article
- Photodynamic Therapy and Dietary Antioxidants: A Dual Strategy for Genome Stability and DNA Damage Repair.Cancer medicine · 2025Review
- Curcumin and acute myeloid leukemia: a golden hope, updated insights.Molecular biology reports · 2025Review
- Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers.Frontiers in pharmacology · 2025Review
- ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma.Cell death & disease · 2024Article
- The Synergistic Effects of Curcumin and Chemotherapeutic Drugs in Inhibiting Metastatic, Invasive and Proliferative Pathways.Plants (Basel, Switzerland) · 2022Review
- Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer.Drug delivery and translational research · 2021Article
- Anacardic Acids fromMolecules (Basel, Switzerland) · 2021Article
- Curcumin suppresses cell growth and attenuates fluoride-mediated Caspase-3 activation in ameloblast-like LS8 cells.Environmental pollution (Barking, Essex : 1987) · 2021Article
- New Protein-Coated Silver Nanoparticles: Characterization, Antitumor and Amoebicidal Activity, Antiproliferative Selectivity, Genotoxicity, and Biocompatibility Evaluation.Pharmaceutics · 2021Article
- Quantitative Chemical Proteomics Reveals Resveratrol Inhibition of A549 Cell Migration Through Binding Multiple Targets to Regulate Cytoskeletal Remodeling and Suppress EMT.Frontiers in pharmacology · 2021Article
- Phytochemicals in Chemoprevention: A Cost-Effective Complementary Approach.Journal of Cancer · 2021Review
- Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia.Antioxidants (Basel, Switzerland) · 2020Review
- Telomeres, DNA Damage and Ageing: Potential Leads from Ayurvedic Rasayana (Anti-Ageing) Drugs.Journal of clinical medicine · 2020Article
- Efficacy of platinum in advanced triple-negative breast cancer with germlineChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells.Frontiers in oncology · 2020Review
- Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy.Journal of cellular physiology · 2019Review
- Curcumin: New Insights into an Ancient Ingredient against Cancer.International journal of molecular sciences · 2019Review
- Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carboplatin, a second-generation platinum agent, has been used as a cancer therapy for decades and exhibits strong anti-tumor activity. However, the wide application of carboplatin is largely limited due to its side effects, especially myelosuppression. Here, we combined carboplatin with curcumin, a natural product that improves tumor-induced anemia, for the treatment of fibrosarcoma to improve the side effects of carboplatin. We first examined the synergistic and attenuated effects of the two agents in a T241-bearing mouse model. The combination therapy caused no obvious synergistic effect, but curcumin significantly improved the survival rate of carboplatin-treated mice. Histologic analysis of the kidney and bone marrow revealed that curcumin improved carboplatin-induced myelosuppression but did not affect the kidney. To determine the mechanism involved, we introduced a probe derived from curcumin to identify its targets in bone marrow cells and the results provided us a clue that curcumin might affect the DNA repair pathway. Western blot analysis revealed that curcumin up-regulated BRCA1, BRCA2 and ERCC1 expression in bone marrow. In conclusion, curcumin attenuates carboplatin-induced myelosuppression by activating the DNA repair pathway in bone marrow cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.